Teva Pharmaceutical ( Teva Pharmaceutical )

Teva Pharmaceutical

Teva Pharmaceutical's picture

The foundation of our success, and at the heart of Teva, is our vision to be the most indispensable medicines company for the world, executing on our obligation to our patients, customers, shareholders and employees.

Established in 1901, today we rank among the 10 top pharmaceutical companies in the world. Headquartered in Israel, Teva is active in 60 countries, with over 46,400 dedicated employees worldwide.

Teva Pharmaceutical press release, blog etc

10/19/2017 - 09:29 Teva to Highlight New Data in Multiple Sclerosis at Joint ECTRIMS ACTRIMS Congress in Paris
10/17/2017 - 10:09 Teva Announces Submission of Biologics License Application for Fremanezumab to the U.S. FDA
10/05/2017 - 08:30 Teva Announces tomys Award Winner at Oncology Satellite Symposium During the 7th International Symposium on Acute Promyelocytic Leukemia (APL) in Rome, Italy
10/04/2017 - 09:44 Teva Comments on Anticipated At-Risk U.S. Launch of Generic Glatiramer Acetate 40mg/mL and Launch of Generic Glatiramer Acetate 20mg/mL
09/25/2017 - 12:51 Teva Announces Reintroduction of Generic Depo-Provera in the United States
09/19/2017 - 08:46 Teva Completes Amendment to Credit Facilities
09/19/2017 - 07:20 Teva and Nuvelution Pharma Partner to Accelerate Development of AUSTEDO (deutetrabenazine) Tablets for Use in Tourette Syndrome in the United States
09/18/2017 - 11:09 New Initiative Creates Scalable Solutions to Improve Care of Patients with Multiple Chronic Conditions
09/18/2017 - 07:49 Teva Announces Sale of Remaining Assets in Specialty Global Womens Health Portfolio for $1.38 Billion
09/14/2017 - 06:31 Teva to Present Data for AUSTEDO (deutetrabenazine) Tablets and Other Research at the 2017 Psych Congress
09/14/2017 - 00:17 Teva Continues to Advance Care for Societys Health and Wellbeing
09/12/2017 - 17:06 Teva Receives FDA Priority Review for First Line Use of TRISENOX (arsenic trioxide) in Patients with Low to Intermediate Risk Acute Promyelocytic Leukemia (APL)
09/11/2017 - 17:49 Teva Announces Sale of PARAGARD (intrauterine copper contraceptive) to CooperSurgical
09/11/2017 - 01:19 Teva Names Kare Schultz as President and Chief Executive Officer
09/09/2017 - 03:46 Teva Showcases Data Demonstrating Potential of Fremanezumab to Address Significant Unmet Need in Patients with Chronic and Episodic Migraine
09/06/2017 - 05:50 Teva To Present New Asthma and COPD Data at the 2017 European Respiratory Society (ERS) International Congress
09/05/2017 - 04:11 Teva to Present Fremanezumab Data on Migraine Prevention at the 18th Congress of the International Headache Society
08/30/2017 - 04:01 Teva Announces FDA Approval of AUSTEDO (deutetrabenazine) Tablets for the Treatment of Tardive Dyskinesia in Adults